Ivan Peyron/ISTH
                         
                                                                  Sep 15, 2025, 17:40 
                                
                                Ivan Peyron Encourages You to Support Resaerch Targeting Rare Coagulation Diseases and Platelet Pathologies
Ivan Peyron, Research Engineer at INSERM, shared on LinkedIn:
Support research!
Bleeding disorders and clotting problems are responsible for many serious illnesses and strokes.
Our mission in the laboratory:
- Deciphering the mechanisms of coagulation
 - Understanding diseases like von Willebrand disease and hemophilia
 - Improving diagnosis and treatment for patients
 
Thanks to our innovative nanobody platform (mini-antibodies) developed since 2014, we create:
- Unique tools for research
 - Promising therapeutic candidates
 
Our current projects target rare coagulation diseases and platelet pathologies, to transform patients’ lives.
- By making a donation, you are directly contributing to:
 - Better Stroke Prevention
 - Improving the management of cardiovascular and inflammatory diseases
 - Bringing hope to thousands of patients around the world
 
Support our research and help us make a difference!”
To support the research, follow the link.
Stay updated on the latest news in the field of clotting disorders with Hemostasis Today.
- 
                    Nov 3, 2025, 08:23The 1st Participant in A New CHECK-NIRS Clinical Study is Enrolled!
 - 
                    Nov 3, 2025, 08:15Bert van Meurs Shares the New Late-breaking Results from the iMODERN Trial
 - 
                    Nov 3, 2025, 07:10Lisa Shea Shares Key Takeaways from NORD Summit 2025
 - 
                    Nov 3, 2025, 06:49Darshan Doshi on Results of iMODERN and ILIAS ANOCA Studies Presented at TCT 2025
 - 
                    Nov 2, 2025, 14:172019 ESC/EAS Guidelines for the Management of Dyslipidaemias Discussion with Lale Tokgözoğlu and Jeanine Roeters van Lennep
 
- 
                    Nov 3, 2025, 09:13Claudio Carrubba on How Timing Truly Matters in Trauma Embolization
 - 
                    Nov 3, 2025, 08:46Rachel Lamerton and Colleagues on Activation of Platelets in Flow Cytometry
 - 
                    Nov 3, 2025, 04:56Nirupama Ramadas and Erica Sparkenbaugh on Thromboinflammation in SCD
 - 
                    Nov 2, 2025, 14:21Claude Franceschi: I Advise You to Understand the Hemodynamic Pathophysiology of Venous Diseases Rather than Blindly Applying Ablation Techniques or Venous Stent Placement
 - 
                    Nov 2, 2025, 14:15Krishna Aragam: Why are (DCM) and Heart Failure About Twice as Common in Individuals of Self-Identified Black Race?
 
- 
                    Oct 29, 2025, 07:31The Use of Artificial Intelligence to Improve Detection of Acute Incidental Pulmonary Emboli - JTH
 - 
                    Oct 29, 2025, 07:05Shrinidhi Nathany: AI in Diagnostic Medicine
 - 
                    Oct 28, 2025, 07:02Aya Berman: AI Model for Predicting Bacteremia
 - 
                    Oct 28, 2025, 06:55The New Era of Genomics, AI and Cell Therapy in Hematology and Infectious Diseases
 - 
                    Oct 28, 2025, 06:49Lukas Gaats: Researchers Are Building Reproductive Organoids
 
- 
                    Nov 3, 2025, 09:24Stephen Cornelissen: It’s Not Just About Emergencies — It’s About Everyday Care, Chronic Conditions and Hope
 - 
                    Nov 3, 2025, 06:57Maria Elisa Mancuso Reflects on 2025 Annual Congress of the Italian Association of Hemophilia Centres
 - 
                    Nov 3, 2025, 05:46Chandra Viswanathan: When Blood Safety Fails, We All Bleed - A Call for Reform and Responsibility
 - 
                    Nov 2, 2025, 14:17Anamaria B: Your Mother Still Runs Part of Your DNA
 - 
                    Nov 2, 2025, 10:57Paul Bolaji on Launching The First Centralised Nigerian National Stroke Registry
 
Nov 3, 2025, 09:13 
                        
                    Nov 3, 2025, 08:23 
                        
                    Nov 3, 2025, 07:10 
                        
                    Nov 3, 2025, 04:56 
                        
                    